News
The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...
New biologic and targeted therapies are changing the landscape of prurigo nodularis care, offering sustained relief and ...
Includes Detailed Profiles of Industry Giants Eli Lilly & Company, Pfizer, Sun Pharmaceutical Industries, Arcutis Biotherapeutics, Bristol-Myers Squibb, AbbVie, Regeneron Pharmaceuticals, and Aclaris ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results